Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Portfolio Pulse from
Foghorn Therapeutics announced that their Phase 1 trial for FHD-286 in combination with decitabine in AML patients showed clinical responses but did not meet the efficacy threshold for continued development by Foghorn alone.
December 16, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Foghorn Therapeutics' Phase 1 trial for FHD-286 in AML patients showed clinical responses but did not meet the efficacy threshold for continued development by Foghorn alone.
The announcement indicates that while there were clinical responses, the results were not strong enough to justify further development by Foghorn alone. This could lead to a negative short-term impact on FHTX stock as investors may be concerned about the future of this drug candidate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100